Analyst Price Targets — NUVB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 11:31 am | — | RBC Capital | $19.00 | $5.60 | TheFly | Nuvation Bio price target lowered to $19 from $20 at RBC Capital |
| January 27, 2026 1:20 pm | — | Truist Financial | $13.00 | $5.66 | TheFly | Nuvation Bio price target raised to $13 from $11 at Truist |
| January 21, 2026 11:35 am | Leonid Timashev | RBC Capital | $12.00 | $6.01 | TheFly | Nuvation Bio price target raised to $12 from $9 at RBC Capital |
| January 12, 2026 1:51 pm | — | H.C. Wainwright | $17.00 | $6.52 | TheFly | Nuvation Bio price target lowered to $17 from $18 at H.C. Wainwright |
| January 7, 2026 5:45 am | Michael Yee | UBS | $10.00 | $8.49 | StreetInsider | UBS Starts Nuvation Bio Inc (NUVB) at Neutral |
| December 11, 2025 11:25 am | — | H.C. Wainwright | $18.00 | $7.89 | TheFly | Nuvation Bio price target raised to $18 from $10 at H.C. Wainwright |
| December 1, 2025 11:34 am | Robert Burns | H.C. Wainwright | $10.00 | $8.04 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB) |
| November 24, 2025 12:21 pm | — | Truist Financial | $11.00 | $6.99 | TheFly | Nuvation Bio initiated with a Buy at Truist |
| November 20, 2025 11:20 am | — | JMP Securities | $10.00 | $7.29 | TheFly | Nuvation Bio price target raised to $10 from $8 at Citizens JMP |
| November 4, 2025 10:45 am | — | JMP Securities | $8.00 | $5.17 | TheFly | Nuvation Bio price target raised to $8 from $6 at Citizens JMP |
Latest News for NUVB
NEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full their over-allotment option (the "Greenshoe Exercise") to purchase an additional $37.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2032…
According to a Form 4 filing, a Nuvation Bio executive reported selling 125,000 Class A shares for a total value of $753,000 on June 23, 2026. This transaction represented 79.32% of Markel Stacy's direct Class A holdings, reducing the direct position to 32,591 shares, though she also retains significant exposure through stock options.
FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PR Newswire NEW
NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the "Offering") of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032 (the "Notes"). The aggregate principal amount of the Offering was increased from…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NUVB.
U.S. House Trading
No House trades found for NUVB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.